Mycosis Fungoides Variants—Clinicopathologic Features, Differential Diagnosis, and Treatment Rein Willemze, MD, Phd

Total Page:16

File Type:pdf, Size:1020Kb

Mycosis Fungoides Variants—Clinicopathologic Features, Differential Diagnosis, and Treatment Rein Willemze, MD, Phd Mycosis fungoides variants—clinicopathologic features, differential diagnosis, and treatment Rein Willemze, MD, PhD slack skin (GSS) are recognized as distinct variants of MF because ■ Abstract of their distinctive clinicopathologic features, clinical behavior, Mycosis fungoides (MF) is the most common type of and/or prognosis.1,7 In this review, the clinical and histopathologic cutaneous T-cell lymphoma, which typically presents with features, differential diagnosis, and treatment of these 3 variants erythematous patches and plaques, histopathologically are presented. Hypopigmented MF, which is the most common characterized by superficial infiltrates of small to medium- sized atypical epidermotropic T cells. Apart from this variant in childhood and adolescence, and other rare variants are classic type of MF, many clinical and/or histopathologic shortly discussed. variants have been described. Correct diagnosis of these MF variants is important, but may be difficult, because they Folliculotropic MF may mimic a wide variety of inflammatory skin diseases. In FMF is a distinct variant of MF characterized by the presence of this review, clinical and histopathologic characteristics of folliculotropic infiltrates, often with sparing of the interfollicular distinct variants of MF are presented, and their differential diagnosis and therapeutic options are discussed. epidermis and preferential involvement of the head and neck re- gion.1 In large series, FMF accounts for approximately 10% of all Semin Cutan Med Surg 37:11-17 © 2018 Frontline patients with MF.2,3 Most cases show mucinous degeneration of the Medical Communications hair follicles (follicular mucinosis) and were originally designated as MF-associated follicular mucinosis. Similar cases, but without follicular mucinosis, have been reported as pilotropic MF.8 ycosis fungoides (MF) is the most common type of cu- It should be emphasized that FMF is defined by a combination taneous T-cell lymphoma (CTCL) and accounts for ap- of clinical and histopathologic criteria. Infiltration of hair follicle Mproximately 50% of all primary cutaneous lymphomas.1 epithelium by neoplastic T cells can also be observed in other types Patients with classical MF present with patches and plaques that of CTCL, such as CD8-positive aggressive epidermotropic cyto- are preferentially located on the buttocks and other covered sites toxic CTCL (CD8+ AECTCL), lymphomatoid papulosis (LyP), of the trunk and limbs (sun-protected areas). Histopathologically, and cases of classic MF, and is in itself insufficient for a diagnosis these early stages are characterized by superficial band-like or li- of FMF.9,10 chenoid infiltrates of small to medium-sized atypical T cells with cerebriform and sometimes hyperchromatic nuclei, which charac- Clinical features teristically infiltrate into the epidermis (epidermotropism). Most FMF mostly presents in adults but has also been reported in patients have a protracted clinical course over years or even de- children and adolescents.11-16 Men are affected more often than cades. However, a proportion of patients may develop nodules or women. Patients may present with (grouped) follicular papules, tumors and eventually progress to extracutaneous disease.2,3 Clas- follicle-based patches, indurated plaques, or tumors, which pref- sic MF, also called Alibert–Bazin type of MF, is discussed in detail erentially involve and are most pronounced in the head and neck in the article by Lorenzo Cerroni in this same issue. area (Figure 1).11-14,17 Other clinical manifestations are acneiform Apart from classical MF, many clinical and/or histopathologic lesions (comedones, cysts) and keratosis pilaris-like lesions that variants of MF mimicking a wide variety of inflammatory skin dis- are mainly localized on trunk and extremities.18 The skin lesions eases have been described.4-6 These include, among others, eryth- are often associated with alopecia. Children most commonly pres- rodermic, hypopigmented, hyperpigmented, bullous/vesicular, ent with hypopigmented folicle-based patches with associated alo- poikilodermatous, folliculotropic, syringotropic, granulomatous, pecia.15 Infiltrated plaques in the eyebrow region with concurrent and even invisible MF. Most variants have a clinical behavior simi- alopecia are a common and highly characteristic finding. Pruritus lar to that of classic MF, and in recent classifications they are there- is often severe and may represent a reliable parameter of disease fore not classified separately. In the WHO European Organization activity. Secondary bacterial infections are frequently observed.17 of Research and Treatment of Cancer (WHO-EORTC) classifica- In rare cases, FMF may present with a solitary skin lesion (solitary tion and in the 2017 revision of the WHO classification, only fol- or unilesional FMF) or with erythroderma.19-21 liculotropic MF (FMF), pagetoid reticulosis, and granulomatous Histopathology and immunophenotype Histopathologically, FMF is characterized by the presence of peri- Department of Dermatology, Leiden University Medical Center, Leiden, The follicular to diffuse infiltrates with variable infiltration of the fol- Netherlands. Disclosures: Dr Willemze has nothing to disclose. licular epithelium by small, medium-sized, or sometimes large T Correspondence: Rein Willemze, MD, PhD; [email protected]; wil- cells with cerebriform and hyperchromatic nuclei (Figure 2).11-14,17 [email protected] Many cases show mucinous degeneration of the follicular epithe- 1085-5629/13$-see front matter © 2018 Frontline Medical Communications Vol 37, March 2018, Seminars in Cutaneous Medicine and Surgery 11 DOI: 10.12788/j.sder.2018.004 ■ ■ ■ Mycosis fungoides variants—clinicopathologic features, differential diagnosis, and treatment A B C D ■ FIGURE 1. Clinical manifestations of FMF. (A) Infiltrated plaque with alopecia and cystic lesions above left eye; (B) grouped follicular papules on right arm; (C) infiltrated plaque with hyperkeratotic papules on left cheek; (D) erythematous tumor and many cystic lesions. FMF, folliculotropic mycosis fungoides. lium (follicular mucinosis), which can be visualized by Alcian blue presence of more than 25% of blast cells or the presence of clusters or colloidal iron staining, but cases without follicular mucinosis of blast cells, has been reported in more than 20% of FMF cases have been described as well.8 Infiltration of the follicular epithe- and is more common than in classical MF.12,14,17 lium may be accompanied by infiltration of the eccrine sweat In virtually all cases, the neoplastic cells in FMF have a CD3+/ glands (syringotropism), a combination that is often referred to as CD4+/CD8− T-cell phenotype as in classic MF.22 Admixed blast adnexotropic MF.21-23 However, concurrent infiltration of the in- cells are often CD30 positive. Most cases show clonal T-cell re- terfollicular epidermis (epidermotropism) characteristic of early- ceptor gene rearrangements.22 stage classic MF is uncommon. In early-stage lesions, clinically characterized by follicle-based patches or acneiform or keratosis Differential diagnosis pilaris-like lesions, the perifollicular infiltrates are generally sparse The distinctive clinical and histopathologic features should facilitate and contain, apart from atypical T cells, variable numbers of small an early and correct diagnosis. However, because of the preferential reactive T cells, histiocytes, and occasionally eosinophils. With involvement of the head and neck area, the absence of patches and progression of the skin lesions to more infiltrated plaques or tu- plaques on the trunk and buttocks, and particularly because of the mors, the dermal infiltrates become more diffuse and may contain absence of epidermotropic atypical T cells, the diagnosis of MF or increasing numbers of blast cells. There is often a considerable CTCL is often not considered and is misinterpreted as seborrheic admixture with eosinophils and, in particular, in cases with sec- dermatitis, atopic dermatitis, or rosacea. Clinicopathologic cor- ondary bacterial infection, plasma cells. In some cases, clusters of relation is also required to differentiate FMF from other types of small B cells may be present. In cases with destruction of the hair CTCL. Because the perifollicular infiltrates often contain scattered follicle epithelium, a granulomatous reaction can be observed.22 In or clusters of CD30-positive blast cells, histopathologic differentia- cases with diffuse dermal infiltrates with partial or even complete tion between FMF and primary cutaneous CD30-positive lymphop- destruction of the epithelial structures, differentiation between roliferations (cutaneous anaplastic large-cell lymphoma; LyP) may FMF and other types of CTCL may be challenging. In such cases, be challenging. In case hair follicles have been destroyed or are com- staining with monoclonal antibodies against keratin may be useful pletely obscured by diffuse dermal infiltrates, it may be difficult or to visualize infiltration of residual hair follicles and sweat glands even impossible to differentiate between FMF and primary cutane- by neoplastic T cells.21 Large-cell transformation, defined by the ous peripheral T-cell lymphoma, unspecified. In such cases, addi- 12 Seminars in Cutaneous Medicine and Surgery, Vol 37, March 2018 Willemze tional biopsies and clinical follow-up are needed to make a definite and abundant, vacuolated cytoplasm. The superficial dermis may diagnosis.21 The relationship between FMF and the so-called benign
Recommended publications
  • Bexarotene (Targretin) Capsules Reference Number: PA.CP.PHAR.75 Effective Date: 09/11 Revision Log Last Review Date: 04/18
    Clinical Policy: Bexarotene (Targretin) Capsules Reference Number: PA.CP.PHAR.75 Effective Date: 09/11 Revision Log Last Review Date: 04/18 Description The intent of the criteria is to ensure that patients follow selection elements established by Pennsylvania Health and Wellness ® clinical policy for bexarotene (Targretin®) capsules FDA Approved Indication(s) Targretin is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Policy/Criteria It is the policy of Pennsylvania Health and Wellness that Targretin is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Cutaneous T-Cell Lymphoma (must meet all): 1. Diagnosis of cutaneous T-cell lymphoma (CTCL) (see Appendix B for CTCL subtypes); 2. Prescribed by or in consultation with an oncologist; 3. Age ≥ 18 years; 4. Dose does not exceed 400mg/m2 daily; Approval duration: 6 months B. Other diagnoses/indications: Refer to PA.CP.PHAR.57 - Global Biopharm Policy. II. Continued Approval A. Cutaneous T-Cell Lymphoma (must meet all): 1. Currently receiving medication via Pennsylvania Health and Wellness benefit or member has previously met all initial approval criteria; or the Continuity of Care policy (PA.LTSS.PHAR.01) applies; 2. Member is responding positively to therapy; 3. Dose does not exceed 400mg/m2 daily; Approval duration: 6months B. Other diagnoses/indications (must meet 1 or 2): 1. Currently receiving medication via Pennsylvania Health and Wellness benefit and documentation supports positive response to therapy; or the Continuity of Care policy (PA.LTSS.PHAR.01) applies; Approval duration: Duration of request or 6 months (whichever is less); or 2.
    [Show full text]
  • Romidepsin (Istodax) Reference Number: ERX.SPA
    Clinical Policy: Romidepsin (Istodax) Reference Number: ERX.SPA. 267 Effective Date: 12.01.18 Last Review Date: 11.20 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Romidepsin (Istodax®) is a histone deacetylase inhibitor. FDA Approved Indication(s) Istodax is indicated for the treatment of: • Cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy; • Peripheral T-cell lymphoma (PTCL) in adult patients who have received at least one prior therapy. o This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Policy/Criteria Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria. Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary. It is the policy of health plans affiliated with Envolve Pharmacy Solutions™ that Istodax and romidepsin injection solution are medically necessary when the following criteria are met: I. Initial Approval Criteria A. Cutaneous T-Cell Lymphoma (must meet all): 1. Diagnosis of CTCL (see Appendix D for examples of CTCL subtypes); 2. Prescribed by or in consultation with an oncologist or hematologist; 3. Age ≥ 18 years; 4. Request meets one of the following (a or b):* a. Dose does not exceed 14 mg/m2 for three days of a 28-day cycle; b.
    [Show full text]
  • Message from the President
    DermNewsletter of the American OsteopathicLine College of Dermatology Spring 2016 Vol. 32, No. 1 Message from the President Greetings from Houston, Texas - again! As President of the AOCD, I welcome you to another edition of DermLine. As I think about our recent past and the dramatic changes afoot, I recall Suzanne Sirota Rozenberg, DO, FAOCD, Past President of AOCD, commenting in the Spring 2014 edition of DermLine about the coming AOA/ACGME merger. As I stated previously, “Today, at this moment, we are living in yesterday’s future.” Our future has arrived. Because the AOA, along with the Accreditation Council for Graduate Medical Education and the American Association of Colleges of Osteopathic Medicine, have agreed to a single accreditation system for graduate medical education programs in the United States, our graduates of osteopathic institutions, along with graduates of allopathic medical schools will complete their residency and/or fellowship education in ACGME-accredited programs and demonstrate achievement of common milestones and competencies side-by-side. I hope you realize the power in the previous statement. Trained together, osteopathic and allopathic graduates will no longer be divided. Perhaps the most exciting news to share is the AAD vote that just passed last month. This has been a battle we have been fighting for generations. The vote suffered defeat in 2004 and 2010. On both occasions, a majority of the membership voted in favor, but the required two-thirds majority required to approve a change to the bylaws fell short. I was told I would never see this vote go through in my lifetime.
    [Show full text]
  • Evaluation of Melanocyte Loss in Mycosis Fungoides Using SOX10 Immunohistochemistry
    Article Evaluation of Melanocyte Loss in Mycosis Fungoides Using SOX10 Immunohistochemistry Cynthia Reyes Barron and Bruce R. Smoller * Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA; [email protected] * Correspondence: [email protected] Abstract: Mycosis fungoides (MF) is a subtype of primary cutaneous T-cell lymphoma (CTCL) with an indolent course that rarely progresses. Histologically, the lesions display a superficial lymphocytic infiltrate with epidermotropism of neoplastic T-cells. Hypopigmented MF is a rare variant that presents with hypopigmented lesions and is more likely to affect young patients. The etiology of the hypopigmentation is unclear. The aim of this study was to assess melanocyte loss in MF through immunohistochemistry (IHC) with SOX10. Twenty cases were evaluated, including seven of the hypopigmented subtype. The neoplastic epidermotropic infiltrate consisted predominantly of CD4+ T-cells in 65% of cases; CD8+ T-cells were present in moderate to abundant numbers in most cases. SOX10 IHC showed a decrease or focal complete loss of melanocytes in 50% of the cases. The predominant neoplastic cell type (CD4+/CD8+), age, race, gender, histologic features, and reported clinical pigmentation of the lesions were not predictive of melanocyte loss. A significant loss of melanocytes was observed in 43% of hypopigmented cases and 54% of conventional cases. Additional studies will increase our understanding of the relationship between observed pigmentation and the loss of melanocytes in MF. Citation: Barron, C.R.; Smoller, B.R. Evaluation of Melanocyte Loss in Keywords: mycosis fungoides; hypopigmented mycosis fungoides; SOX10; cutaneous T-cell lymphoma Mycosis Fungoides Using SOX10 Immunohistochemistry.
    [Show full text]
  • Prostatic Cryptococcosis - a Case Report
    Received: November 8, 2007 J. Venom. Anim. Toxins incl. Trop. Dis. Accepted: April 1, 2008 V.14, n.2, p.378-385, 2008. Abstract published online: April 2, 2008 Case report. Full paper published online: May 31, 2008 ISSN 1678-9199. PROSTATIC CRYPTOCOCCOSIS - A CASE REPORT CHANG M. R. (1), PANIAGO A. M. M. (2), SILVA M. M. (3), LAZÉRA M. S. (4), WANKE B. (4) (1) Department of Pharmacy-Biochemistry, Federal University of Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul State, Brazil; (2) Department of Internal Medicine, UFMS, Campo Grande, Mato Grosso do Sul State, Brazil; (3) Medicine Program, University for Development of the State and the Pantanal Region (UNIDERP), Campo Grande, Mato Grosso do Sul State, Brazil; (4) Mycology Service Evandro Chagas Institute of Clinical Research (IPEC), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Rio de Janeiro State, Brazil. ABSTRACT: Cryptococcosis is a systemic mycosis usually affecting immunodeficient individuals. In contrast, immunologically competent patients are rarely affected. Dissemination of cryptococcosis usually involves the central nervous system, manifesting as meningitis or meningoencephalitis. Prostatic lesions are not commonly found. A case of prostate cryptococcal infection is presented and cases of prostatic cryptococcosis in normal and immunocompromised hosts are reviewed. A fifty-year-old HIV-negative man with urinary retention and renal insufficiency underwent prostatectomy due to massive enlargement of the organ. Prostate histopathologic examination revealed encapsulated yeast-like structures. After 30 days, the patient’s clinical manifestations worsened, with headache, neck stiffness, bradypsychia, vomiting and fever. Direct microscopy of the patient’s urine with China ink preparations showed capsulated yeasts, and positive culture yielded Cryptococcus neoformans.
    [Show full text]
  • Primary Cutaneous Lymphoma: ESMO Clinical Recommendations for Diagnosis, Treatment and Follow-Up R
    Annals of Oncology 19 (Supplement 2): ii72–ii76, 2008 clinical recommendations doi:10.1093/annonc/mdn095 Primary cutaneous lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up R. Dummer1 & M. Dreyling2 On behalf of the ESMO Guidelines Working Group* 1Department of Dermatology, University Hospital, Zu¨rich, Switzerland; 2Department of Medicine III, University Hospital Grosshadern, Munich, Germany introduction the quality of life due to their impact on skin appearance and annoying symptoms such as pruritus. In some cases they can Cutaneous lymphomas (CL) are the second most common already be disfiguring in early disease stages. In advanced stages, extranodal non-Hodgkin’s lymphomas. Their incidence is local skin problems are accompanied by systemic immune estimated at 1/100 000 yearly. Primary CL develop by definition suppression which results in an increased risk of infections and in the skin and remain confined to the skin for a long period of secondary malignancies. Some of the late-stage problems in time, while secondary CL reflect cutaneous spread from MF/SS patients might have been aggravated by earlier disseminated primary nodal or extranodal lymphomas. Primary therapeutic interventions, e.g. radiotherapy or phototherapy CL include a wide spectrum of clinically and histologically may contribute to mutations that increase the proliferative heterogeneous lymphoproliferative neoplasms: 75% of CL are and invasive capacity of the tumor cell populations. Cytotoxic cutaneous T-cell lymphomas (CTCL); 25% cutaneous B-cell drugs favor infectious complications. Most patients with lymphomas (CBCL); and a few percent other uncommon advanced disease may die due to secondary problems such as forms. CL and nodal or extracutaneous lymphomas with the infections.
    [Show full text]
  • Treatment of Pagetoid Reticulosis with Intensity Modulated Radiation Therapy Charles Mount Washington University School of Medicine in St
    Washington University School of Medicine Digital Commons@Becker Open Access Publications 2014 Treatment of pagetoid reticulosis with intensity modulated radiation therapy Charles Mount Washington University School of Medicine in St. Louis Daniel Ferraro Washington University School of Medicine in St. Louis Alejandro Gru Washington University School of Medicine in St. Louis Matthew rB adbury Washington University School of Medicine in St. Louis Lynn Cornelius Washington University School of Medicine in St. Louis See next page for additional authors Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Recommended Citation Mount, Charles; Ferraro, Daniel; Gru, Alejandro; Bradbury, Matthew; Cornelius, Lynn; and Gay, Hiram, ,"Treatment of pagetoid reticulosis with intensity modulated radiation therapy." Dermatology Online Journal.20,10. (2014). https://digitalcommons.wustl.edu/open_access_pubs/5149 This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. Authors Charles Mount, Daniel Ferraro, Alejandro Gru, Matthew Bradbury, Lynn Cornelius, and Hiram Gay This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/5149 Dermatology Online Journal UC Davis Peer Reviewed Title: Treatment of pagetoid reticulosis with intensity modulated radiation therapy Journal Issue: Dermatology Online Journal, 20(10) Author: Mount, Charles, Washington University in St. Louis Ferraro, Daniel, Washington University in St. Louis Gru, Alejandro, Washington University in St. Louis; The Ohio State University Bradbury, Matthew, Washington University in St. Louis Cornelius, Lynn, Washington University in St.
    [Show full text]
  • Fungal Foot Infection: the Hidden Enemy?
    Clinical REVIEW Fungal foot infection: the hidden enemy? When discussing tissue viability in the lower limb, much attention is focused on the role of bacterial infection. However, fungal skin infection is a more frequent and more recurrent pathogen which often goes undetected by the practitioner and patient alike. Potentially, untreated fungal foot infection can facilitate secondary problems such as superficial bacterial infections, or, more seriously, lower limb cellulitis. Often simple measures can prevent fungal foot infection and therefore reduce the possibility of complications. This article will review the presentation of tinea pedis and onychomycosis, their effects and management. Ivan Bristow, Manfred Mak Under occlusive and humid conditions increased risk of acquiring the infection. KEY WORDS the fungal hyphae then develop and Patients with diabetes show an increased invade the deeper stratum corneum. susceptibility (Yosipovitch et al, 1998). Fungal Nutrition is afforded by the extra-cellular Boyko et al (2006) have identified the Tinea pedis secretion of proteolytic and keratolytic presence of tinea to be a predictor of Onchomycosis enzymes breaking down the complex foot ulceration in a diabetic population. Cellulitis keratin into simple molecules which can The reason for an increased prevalence be absorbed by the organism (Kaufman in patients with diabetes remains under- et al, 2007). researched. It has been proposed that peripheral neuropathy renders the foot Epidemiology of fungal foot infection insensate reducing individual awareness inea pedis (athlete’s foot) is an Fungal foot infection (FFI) is the most to the presence of infection. Eckhard et inflammatory condition and common infection found on the foot. al (2007) discovered a high prevalence Trepresents the most common of Seldom seen before puberty, the in patients with type 2 diabetes who all the superficial fungal skin infections prevalence rises with age, peaking in the exhibited a lack of sweating when tested (Hay, 1993).
    [Show full text]
  • Allergic Bronchopulmonary Aspergillosis
    Allergic Bronchopulmonary Aspergillosis Karen Patterson1 and Mary E. Strek1 1Department of Medicine, Section of Pulmonary and Critical Care Medicine, The University of Chicago, Chicago, Illinois Allergic bronchopulmonary aspergillosis (ABPA) is a complex clinical type of pulmonary disease that may develop in response to entity that results from an allergic immune response to Aspergillus aspergillus exposure (6) (Table 1). ABPA, one of the many fumigatus, most often occurring in a patient with asthma or cystic forms of aspergillus disease, results from a hyperreactive im- fibrosis. Sensitization to aspergillus in the allergic host leads to mune response to A. fumigatus without tissue invasion. activation of T helper 2 lymphocytes, which play a key role in ABPA occurs almost exclusively in patients with asthma or recruiting eosinophils and other inflammatory mediators. ABPA is CF who have concomitant atopy. The precise incidence of defined by a constellation of clinical, laboratory, and radiographic ABPA in patients with asthma and CF is not known but it is criteria that include active asthma, serum eosinophilia, an elevated not high. Approximately 2% of patients with asthma and 1 to total IgE level, fleeting pulmonary parenchymal opacities, bronchi- 15% of patients with CF develop ABPA (2, 4). Although the ectasis, and evidence for sensitization to Aspergillus fumigatus by incidence of ABPA has been shown to increase in some areas of skin testing. Specific diagnostic criteria exist and have evolved over the world during months when total mold counts are high, the past several decades. Staging can be helpful to distinguish active disease from remission or end-stage bronchiectasis with ABPA occurs year round, and the incidence has not been progressive destruction of lung parenchyma and loss of lung definitively shown to correlate with total ambient aspergillus function.
    [Show full text]
  • Histopathological Reporting of Malignant Lymphoma
    Malaysian J Path01 1999; 21(1): 63 - 67 CONSENSUS REPORT Histopathological reporting of malignant lymphoma Suat-Cheng Peh and *Sibrand Poppema Chairman and *invited consultant, Organizing Committee, Slide Seminar-cum-Workshop on Malignant Lymphoma 1999 A consensus on histopathology reporting of malignant lymphoma was reached at the "Slide Seminar- cum-Workshop on Malignant Lymphoma," jointly organized by the Malaysian Society of Pathologists and the Department of Pathology, Faculty of Medicine, University of Malaya on 29 -30 April, 1999. I. CLASSIFICATION It was agreed that the newly proposed World Health Organization classification of Neoplastic Diseases of Hematopoietic and Lymphoid Tissue will be adopted (Table 1). Individual institutions may in addition include in their reports the classification currently in use in these centres in the initial phase, until clinicians are familiar with the entities listed in the WHO classification. 11. IMMUNOHISTOCHEMISTRY It was also agreed that immunohistological investigation is frequently essential for a correct lymphoma diagnosis. The following was recommended for the study on paraffin-embedded biopsy material: a. Panel of antibodies for routine application: CD20 (L26) or CD79a CD3 (polyclonal CD3) or CD43 (MT1) CD45RO (UCHL1) Kappa and Lambda light chains b. Panel of useful additional antibodies: CD15 CD30 CD45 (LCA) S loo CD68 Cytokeratin Bcl-2 Vimentin c. Others: CD5 CD21 CD23 CD56 ALK Malaysiun J Pathol June 1999 111. THE HISTOPATHOLOGY REPORT The following items should be included in the histology report: 1. Identification: Whether biopsy material is nodal or extra-nodal tissue. 2. Description of the lesion: i. Whether normal structure is preserved ii. Describe the pattern of architectural distortion, e.g.
    [Show full text]
  • Mycosis Fungoides and Sézary Syndrome: an Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy
    cancers Review Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy Nuria García-Díaz 1 , Miguel Ángel Piris 2,† , Pablo Luis Ortiz-Romero 3,† and José Pedro Vaqué 1,*,† 1 Molecular Biology Department, Universidad de Cantabria—Instituto de Investigación Marqués de Valdecilla, IDIVAL, 39011 Santander, Spain; [email protected] 2 Department of Pathology, Fundación Jiménez Díaz, CIBERONC, 28040 Madrid, Spain; [email protected] 3 Department of Dermatology, Hospital 12 de Octubre, Institute i+12, CIBERONC, Medical School, University Complutense, 28041 Madrid, Spain; [email protected] * Correspondence: [email protected] † Same contribution. Simple Summary: In the last few years, the field of cutaneous T-cell lymphomas has experienced major advances. In the context of an active translational and clinical research field, next-generation sequencing data have boosted our understanding of the main molecular mechanisms that govern the biology of these entities, thus enabling the development of novel tools for diagnosis and specific therapy. Here, we focus on mycosis fungoides and Sézary syndrome; we review essential aspects of their pathophysiology, provide a rational mechanistic interpretation of the genomic data, and discuss the current and upcoming therapies, including the potential crosstalk between genomic alterations Citation: García-Díaz, N.; Piris, M.Á.; and the microenvironment, offering opportunities for targeted therapies. Ortiz-Romero, P.L.; Vaqué, J.P. Mycosis Fungoides and Sézary Abstract: Primary cutaneous T-cell lymphomas (CTCLs) constitute a heterogeneous group of diseases Syndrome: An Integrative Review of that affect the skin. Mycosis fungoides (MF) and Sézary syndrome (SS) account for the majority the Pathophysiology, Molecular of these lesions and have recently been the focus of extensive translational research.
    [Show full text]
  • Immunotherapy in the Prevention and Treatment of Chronic Fungal Infections
    A chance for treatment - immunotherapy in the prevention and treatment of chronic fungal infections Frank L. van de Veerdonk Radboud Center for Infectious diseases (RCI) ESCMID eLibrary © by author Candida infections Mucocutaneous infections Invasive candidiasis Th ESCMIDT helper cells eLibraryPhagocytes © by author Chronic Candida infection 30% to 50% of individuals are colonized with Candida at any given moment, but only rarely causing mucosal infections Even more rarely are these infections chronic However, several clinical syndromes have been described with chronic CandidaESCMIDinfections eLibrary © by author Mucosal host defence against Candida ESCMID eLibrary Nature Microbiol. Reviews 2012 © by author Mucosal host defence against Candida ESCMID eLibrary Nature Microbiol. Reviews 2012 © by author Chronic Candida infections Hyper IgE syndrome (HIES) Dectin-1/CARD9 deficiency Chronic mucocutaneous candidiasis (STAT1 GOF, APECED, IL-17F, IL-17R) ESCMID eLibrary © by author Characteristics of Hyper IgE syndrome ESCMID eLibrary © by author Loss of function STAT3 mutation Heterozygous mutation in STAT3 ESCMIDDominant negative eLibrary © by author Cytokine signalling INTERLEUKIN-6/23 IL-6/IL-23 RECEPTOR STAT3 phosphorylation IL-17 ESCMID eLibrary PMN Levy and Loomis et al, NEJM 2007 © by author Th17 deficiency in HIES IL-17 ESCMID eLibrary IFNg van de Veerdonk et al, Clin Exp Immunol© 2010by author Chronic Candida infections Hyper IgE syndrome (HIES) Dectin-1/CARD9 deficiency Chronic mucocutaneous candidiasis ESCMID eLibrary © by author
    [Show full text]